Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488-499.
Shek D, Gloss B, Lai J, et al. Identification and characterisation of infiltrating immune cells in malignant pleural mesothelioma using spatial transcriptomics. Methods Protoc. 2023;6(2):35.
Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550.
Jiang X, Zhou T, Xiao Y, et al. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. OncoImmunology. 2016;5(9):e1211219.
Midro AT, Panasiuk B, Tümer Z, et al. Interstitial deletion 9q22.32-q33.2 associated with additional familial translocation t(9;17)(q34.11;p11.2) in a patient with Gorlin-Goltz syndrome and features of Nail-Patella syndrome. Am J Med Genet. 2004;124A(2):179-191.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).